PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi

Irene N Njuguna, Gwen Ambler, Marie Reilly, Beatrice Ondondo, Mercy Kanyugo, Barbara Lohman-Payne, Christine Gichuhi, Nicola Borthwick, Antony Black, Shams-Rony Mehedi, Jiyu Sun, Elizabeth Maleche-Obimbo, Bhavna Chohan, Grace C John-Stewart, Walter Jaoko, Tomáš Hanke, Irene N Njuguna, Gwen Ambler, Marie Reilly, Beatrice Ondondo, Mercy Kanyugo, Barbara Lohman-Payne, Christine Gichuhi, Nicola Borthwick, Antony Black, Shams-Rony Mehedi, Jiyu Sun, Elizabeth Maleche-Obimbo, Bhavna Chohan, Grace C John-Stewart, Walter Jaoko, Tomáš Hanke

Abstract

Background: A safe, effective vaccine for breastfeeding infants born to HIV-1-positive mothers could complement antiretroviral therapy (ART) for prevention of mother-to-child transmission of HIV-1. To date, only a few HIV-1 vaccine candidates have been tested in infants.

Trial design: A phase I/II randomized controlled trial PedVacc 002 was conducted to determine the safety and immunogenicity of a single, low dose of MVA.HIVA vaccine delivered intramuscularly to healthy 20-week-old infants born to HIV-1-positive mothers in Nairobi, Kenya.

Methods: Pregnant HIV-1-positive women in the 2nd/3rd trimester of gestation were enrolled, provided with ART and self-selected their infant-feeding modality. Infants received nevirapine and cotrimoxazole prophylaxis. At 20 weeks of age, eligible HIV-1-negative infants were randomized to vaccine versus no-treatment arms and followed to 48 weeks of age for assessments of vaccine safety, HIV-1-specific T-cell responses and antibodies to routine childhood vaccines.

Results: Between February and November 2010, 182 mothers were screened, 104 were eligible and followed on ART during pregnancy/postpartum, of whom 73 had eligible infants at 20 weeks postpartum. Thirty-six infants were randomized to vaccine and 37 to no treatment. Eighty-four percent of infants breastfed, and retention at 48 weeks was 99%. Adverse events were rare and similar between the two arms. HIV-1-specific T-cell frequencies in interferon-γ ELISPOT assay were transiently higher in the MVA.HIVA arm (p=0.002), but not above the threshold for a positive assay. Protective antibody levels were adequate and similar between arms for all routine childhood vaccines except HBV, where 71% of MVA.HIVA subjects compared to 92% of control subjects were protected (p=0.05).

Conclusions: This trial tested for the first time an MVA-vectored candidate HIV-1 vaccine in HIV-1-exposed infants in Africa, demonstrating trial feasibility and vaccine safety, low immunogenicity, and compatibility with routine childhood vaccinations. These results are reassuring for use of the MVA vector in more potent prime-boost regimens.

Trial registration: ClinicalTrials.gov NCT00981695.

Keywords: EPI vaccines; Exposed-uninfected infants; HIV-1; Infant vaccine trial in Africa; KEPI vaccines; Modified vaccinia virus Ankara (MVA); Pediatric HIV-1 vaccines.

Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Trial profile. Diagram indicating the numbers of infants screened and followed up throughout the study.

References

    1. Bae W.H., Wester C., Smeaton L.M., Shapiro R.L., Lockman S., Onyait K. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS. 2008;22:1633–1640.
    1. Chappuy H., Treluyer J.M., Jullien V., Dimet J., Rey E., Fouche M. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48:4332–4336.
    1. Chappuy H., Treluyer J.M., Rey E., Dimet J., Fouche M., Firtion G. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004;191:558–562.
    1. Feiterna-Sperling C., Weizsaecker K., Buhrer C., Casteleyn S., Loui A., Schmitz T. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr. 2007;45:43–51.
    1. Njuguna I., Reilly M., Jaoko W., Gichuhi C., Ambler G., Maleche-Obimbo E. Infant neutrapenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of HIV. Retrovirology. 2014;6:1–5.
    1. Pacheco S.E., McIntosh K., Lu M., Mofenson L.M., Diaz C., Foca M. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis. 2006;194:1089–1097.
    1. Shapiro R.L., Holland D.T., Capparelli E., Lockman S., Thior I., Wester C. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720–727.
    1. Six Week Extended-Dose Nevirapine Study, Bedri T.A., Gudetta B., Isehak A., Kumbi S., Lulseged S. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372:300–313.
    1. Richardson B.A., Mbori-Ngacha D., Lavreys L., John-Stewart G.C., Nduati R., Panteleeff D.D. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol. 2003;77:7120–7123.
    1. Mo H., Monard S., Pollack H., Ip J., Rochford G., Wu L. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses. 1998;14:607–617.
    1. Luzuriaga K., Sullivan J.L. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev. 2002;4:21–26.
    1. Farber D.L., Yudanin N.A., Restifo N.P. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14:24–35.
    1. Cunningham C.K., McFarland E. Vaccines for prevention of mother-to-child transmission of HIV. Curr Opin HIV AIDS. 2008;3:151–154.
    1. Gomez C.E., Perdiguero B., Garcia-Arriaza J., Esteban M. Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines. 2013;12:1395–1416.
    1. Hanke T., Goonetilleke N., McMichael A.J., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J Gen Virol. 2007;88:1–12.
    1. Hanke T., McMichael A.J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med. 2000;6:951–955.
    1. Borkowsky W., Wara D., Fenton T., McNamara J., Kang M., Mofenson L. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis. 2000;181:890–896.
    1. Cunningham C.K., Wara D.W., Kang M., Fenton T., Hawkins E., McNamara J. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis. 2001;32:801–807.
    1. McFarland E.J., Borkowsky W., Fenton T., Wara D., McNamara J., Samson P. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis. 2001;184:1331–1335.
    1. Johnson D.C., McFarland E.J., Muresan P., Fenton T., McNamara J., Read J.S. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis. 2005;192:2129–2133.
    1. McFarland E.J., Johnson D.C., Muresan P., Fenton T., Tomaras G.D., McNamara J. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS. 2006;20:1481–1489.
    1. Kintu K., Andrew P., Musoke P., Richardson P., Asiimwe-Kateera B., Nakyanzi T. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr. 2013;63:1–8.
    1. Afolabi M.O., Ndure J., Drammeh A., Darboe F., Mehedi S.-R., Rowland-Jones S.L. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS One. 2013;8:e78289.
    1. van Gageldonk P.G., van Schaijk F.G., van der Klis F.R., Berbers G.A. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335:79–89.
    1. Eggers M., Terletskaia-Ladwig E., Rabenau H.F., Doerr H.W., Diedrich S., Enders G. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany. BMC Infect Dis. 2010;10:347.
    1. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A., Brittain N.J. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med. 2011;3:88ra56.
    1. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L., Mauff K. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203:1832–1843.
    1. Hanke T. Conserved immunogens in prime-bost strategies for te next-generation HIV-1 vaccines. Expert Opin Biol Ther. 2014;14:601–616.
    1. Hopkins R., Bridgeman A., Bourne C., Mbewe-Mwula A., Sadoff J.C., Both G.W. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol. 2011;41:3542–3552.
    1. Hopkins R., Bridgeman A., Joseph J., Gilbert S.C., McShane H., Hanke T. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One. 2011;6:e20067.
    1. Im E.J., Saubi N., Virgili G., Sander C., Teoh D., Gatell J.M. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol. 2007;81:9408–9418.
    1. Rosario M., Fulkerson J., Soneji S., Parker J., Im E.J., Borthwick N. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J Virol. 2010;84:7815–7821.
    1. Rosario M., Hopkins R., Fulkerson J., Borthwick N., Quigley M.F., Joseph J. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J Virol. 2010;84:5898–5908.
    1. Saubi N., Gea-Mallorqui E., Ferrer P., Hurtado C., Sanchez-Ubeda S., Eto Y. Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG. Mol Ther Methods Clin Dev. 2014;1:14017.
    1. Saubi N., Im E.J., Fernandez-Lloris R., Gil O., Cardona P.J., Gatell J.M. Newborn mice vaccination with BCG.HIVA + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin Dev Immunol. 2011;2011:516219.
    1. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., Ebrahimsa U. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014;22:464–475.
    1. Ewer K.J., O‘Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836.
    1. Sheehy S.H., Duncan C.J., Elias S.C., Choudhary P., Biswas S., Halstead F.D. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2013;20:2355–2368.
    1. Letourneau S., Im E.-J., Mashishi T., Brereton C., Bridgeman A., Yang H. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One. 2007;2:e984.
    1. McMichael A.J., Haynes B.F. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol. 2012;13:423–427.
    1. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004;10:1240–1244.
    1. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381:1021–1028.
    1. Clerici M., Saresella M., Colombo F., Fossati S., Sala N., Bricalli D. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood. 2000;96:3866–3871.
    1. Kidzeru E.B., Hesseling A.C., Passmore J.A., Myer L., Gamieldien H., Tchakoute C.T. In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants. AIDS. 2014
    1. Miyamoto M., Pessoa S.D., Ono E., Machado D.M., Salomao R., Succi R.C. Low CD4+ T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents. J Trop Pediatr. 2010;56:427–432.
    1. Nielsen S.D., Jeppesen D.L., Kolte L., Clark D.R., Sorensen T.U., Dreves A.M. Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood. 2001;98:398–404.
    1. Jones S.A., Groome M., Koen A., Van Niekerk N., Sewraj P., Kuwanda L. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One. 2013;8:e72794.
    1. Abramczuk B.M., Mazzola T.N., Moreno Y.M., Zorzeto T.Q., Quintilio W., Wolf P.S. Impaired humoral response to vaccines among HIV-exposed uninfected infants. Clin Vaccine Immunol. 2011;18:1406–1409.
    1. Thaithumyanon P., Punnahitananda S., Praisuwanna P., Thisyakorn U., Ruxrungtham K. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai. 2002;85:277–282.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi